In recent months, plenty of pharmaceutical and biotech stocks have managed to record significant gains. However, some stocks can sometimes remain under the radar and that may be the case with regards to the Strongbridge Biopharma plc (NASDAQ: SBBP) stock.
That being said, it should be noted that the Strongbridge stock has performed strongly this year so far and managed to deliver growth of as high as 35%. Experts believe that the company’s stock could be approaching an inflection point this year and that is related to one of its products.
First and foremost, it should be noted that Strongbridge had provided strong projections with regards to its performance in the fourth quarter. However, the most important thing to keep in mind is the potential approval of its product RECORLEV from the United States Food and Drug Administration. Hence, it could be a good idea for investors to keep an eye out for any developments with regards to the product.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.